Trial Profile
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofersen (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ionis Pharmaceuticals
- 12 Apr 2012 Actual patient number is 33 according to ClinicalTrials.gov.
- 12 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.